Key result
UK primary care survey evaluates preferred secondary prevention LDL-C targets without reporting quantitative findings.
Why the study?
There is uncertainty about the preferred LDL-C targets among UK primary care healthcare professionals given differing NICE 2023 and ESC 2025 guideline recommendations.
Cross-Sectional
Explores preferred secondary prevention LDL-C targets among UK healthcare professionals, highlighting tensions between cost-effective NICE guidelines and intensive ESC recommendations.
Background and Aims: Background: Lipid-lowering therapy (LLT) is essential for reducing atherosclerotic CVD (ASCVD) risk, with greater reductions in LDL-C associated with lower ASCVD event rates. The NICE 2023 guidelines, which are based on cost-effectiveness, advise an LDL-C target of ≤ 2.0 mmol/L in patients with established ASCVD, whereas the ESC 2025 guidelines advise a more aggressive clinical target of < 1.4 mmol/L for patients considered to be at very high risk, or < 1.0 mmol/L for patients considered to be at extreme risk.1,2 Aims: To explore the preferred LDL-C targets (NICE vs ESC) of UK primary care healthcare professionals (HCPs)
No takes yet. Share an insight, caveat, or question.
Thakkar et al. (2026) conducted a cross-sectional in Atherosclerotic cardiovascular disease (ASCVD) management. Preferences for ESC vs NICE LDL-C guidelines was evaluated on Preferred LDL-C targets (NICE vs ESC). The truncated abstract only outlined the aim to explore preferred secondary prevention LDL-C targets among UK primary care healthcare professionals, with no quantitative results reported.
Synapse has enriched 5 related papers. Consider them for comparative context: